WO2005012318A2 - Substituted fused heterocyclic c-glycosides - Google Patents
Substituted fused heterocyclic c-glycosides Download PDFInfo
- Publication number
- WO2005012318A2 WO2005012318A2 PCT/US2004/024625 US2004024625W WO2005012318A2 WO 2005012318 A2 WO2005012318 A2 WO 2005012318A2 US 2004024625 W US2004024625 W US 2004024625W WO 2005012318 A2 WO2005012318 A2 WO 2005012318A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- phenyl
- glucose
- glucopyranosyl
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Definitions
- This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.
- Diabetes is a chronic disorder affecting carbohydrate, fat and protein metabolism in animals.
- Type I diabetes mellitus which comprises approximately 10% of all diabetes cases, was previously referred to as insulin-dependent diabetes mellitus ("IDDM") or juvenile-onset diabetes.
- IDDM insulin-dependent diabetes mellitus
- This disease is characterized by a progressive loss of insulin secretory function by beta cells of the pancreas. This characteristic is also shared by non-idiopathic, or "secondary", diabetes having its origins in pancreatic disease.
- Type I diabetes mellitus is associated with the following clinical signs or symptoms: persistently elevated plasma glucose concentration or hyperglycemia; polyuria; polydipsia and/or hyperphagia; chronic microvascular complications such as retinopathy, nephropathy and neuropathy; and macrovascular complications such as hyperlipidemia and hypertension which can lead to blindness, end-stage renal disease, limb amputation and myocardial infarction.
- Type II diabetes mellitus is a metabolic disorder involving the dysregulation of glucose metabolism and impaired insulin sensitivity.
- Type II diabetes mellitus usually develops in adulthood and is associated with the body's inability to utilize or make sufficient insulin.
- patients suffering from type II diabetes mellitus have a relative insulin deficiency - that is, patients have lower than predicted insulin levels for a given plasma glucose concentration.
- Type II diabetes mellitus is characterized by the following clinical signs or symptoms: persistently elevated plasma glucose concentration or hyperglycemia; polyuria; polydipsia and/or hyperphagia; chronic microvascular complications such as retinopathy, nephropathy and neuropathy; and macrovascular complications such as hyperlipidemia and hypertension which can lead to blindness, end-stage renal disease, limb amputation and myocardial infarction.
- Insulin Resistance Syndrome X also termed Insulin Resistance Syndrome (IRS), Metabolic Syndrome, or Metabolic Syndrome X
- IGS Insulin Resistance Syndrome
- Metabolic Syndrome X is recognized in some 2% of diagnostic coronary catheterizations. Often disabling, it presents symptoms or risk factors for the development of Type II diabetes mellitus and cardiovascular disease, including impaired glucose tolerance (IGT), impaired fasting glucose (IFG), hyperinsulinemia, insulin resistance, dyslipidemia (e.g., high triglycerides, low HDL), hypertension and obesity.
- IIGT impaired glucose tolerance
- IGF impaired fasting glucose
- hyperinsulinemia insulin resistance
- dyslipidemia e.g., high triglycerides, low HDL
- exogenous insulin which may be derived from various sources (e.g., human, bovine, porcine insulin).
- sources e.g., human, bovine, porcine insulin.
- heterologous species material gives rise to formation of anti-insulin antibodies which have activity-limiting effects and result in progressive requirements for larger doses in order to achieve desired hypoglycemic effects.
- Type II diabetes mellitus Typical treatment of Type II diabetes mellitus focuses on maintaining the blood glucose level as near to normal as possible with lifestyle modification relating to diet and exercise, and when necessary, the treatment with anti- diabetic agents, insulin or a combination thereof. NIDDM that cannot be controlled by dietary management is treated with oral antidiabetic agents.
- insulin resistance is not always treated in all Syndrome X patients, those who exhibit a prediabetic state (e.g., IGT, IFG), where fasting glucose levels may be higher than normal but not at the diabetes diagnostic criterion, is treated in some countries (e.g., Germany) with metformin to prevent diabetes.
- the anti-diabetic agents may be combined with pharmacological agents for the treatment of the concomitant co-morbidities (e.g., antihypertensives for hypertension, hypolipidemic agents for lipidemia).
- First-line therapies typically include metformin and sulfonylureas as well as thiazolidinediones.
- Metformin monotherapy is a first line choice, particularly for treating type II diabetic patients who are also obese and/or dyslipidemic. Lack of an appropriate response to metformin is often followed by treatment with metformin in combination with sulfonylureas, thiazolidinediones, or insulin.
- Sulfonylurea monotherapy (including all generations of drugs) is also a common first line treatment option.
- Another first line therapy choice may be thiazolidinediones.
- Alpha glucosidase inhibitors are also used as first and second line therapies.
- One aspect of the present invention is directed to methods and compositions for the treatment or prophylaxis of diabetes, Syndrome X, or associated symptoms or complications. More specifically, this invention is directed to a novel method of treating diabetes or Syndrome X, or associated symptoms or complications thereof, in a subject afflicted with such a condition, said method comprising administering one or more glucose reabsorption inhibitors and administering one or more antidiabetic agent(s) for the treatment of diabetes or Syndrome X, or associated symptoms or complications thereof.
- Another aspect of the invention features compounds of formula (IV)
- one of the dashed lines between NRi and X or between X and Y is present, or both are absent; two of V, M, and W are H and the third is
- Ri is H, or C ⁇ - 4 alkyl; or R-i is absent where the dashed line between NR 1 and X is present,
- Y is CH, where X is C-Q-Z;
- Z is substituted or unsubstituted, and is selected from C 3 - 7 cycloalkyl, phenyl, a 5- or 6- membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, a 9- or 10-membered fused bicyclyl (such as naphthyl), and a fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms (and preferably between 1 and 3 or between 1 and 2 heteroatoms) independently selected from N, O, and S;
- P H, C 1 . 7 acyl, or (C ⁇ - 6 alkoxy)carbonyl;
- One aspect of the invention features a pharmaceutical composition comprising a glucose reabsorption inhibitor, at least one additional antidiabetic agent, and a pharmaceutically acceptable carrier.
- the invention also provides a process for formulating a pharmaceutical composition, comprising formulating together a glucose reabsorption inhibitor, one or more antidiabetic agent(s), and a pharmaceutically acceptable carrier.
- An embodiment of the invention is a method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a subject, said method comprising administering to said subject a jointly effective amount of a glucose reabsorption inhibitor and administering to said subject a jointly effective amount of at least one antidiabetic agent, said combined administration providing the desired therapeutic effect.
- Another embodiment of the invention is a method for inhibiting the onset of diabetes or Syndrome X, or associated symptoms or complications thereof in a subject, said method comprising administering to said subject a jointly effective dose of a glucose reabsorption inhibitor and administering to said subject a jointly effective amount of one or more anti-diabetic agent(s), said combined administration providing the desired prophylactic effect.
- the diabetes or Syndrome X is selected from IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.
- Also included in the invention is the use of one or more glucose reabsorption inhibitors in combination with one or more antidiabetic agents for the preparation of a medicament for treating a condition selected from IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome or polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.
- US Patent NO. 6,153,632 to R. Rieveley discloses a method and composition stated to be for the treatment of diabetes mellitus (Type I, Impaired Glucose Tolerance ["IGT”] and Type II), which incorporates a therapeutic amount of one or more insulin sensitizers along with one or more of an orally ingested insulin, an injected insulin, a sulfonylurea, a biguanide or an alpha-glucosidase inhibitor for the treatment of diabetes mellitus.
- Type I Impaired Glucose Tolerance ["IGT”] and Type II
- the invention features the combination of a PPAR modulator, preferably a PPAR ⁇ agonist, and an SGLT inhibitor, preferably an SGLT 2 inhibitor or a selective SGLT 2 inhibitor.
- a PPAR modulator preferably a PPAR ⁇ agonist
- an SGLT inhibitor preferably an SGLT 2 inhibitor or a selective SGLT 2 inhibitor.
- alkyl and alkoxy as used herein, whether used alone or as part of a substituent group, include straight, cyclic, and branched-chain alkyl having 1 to 8 carbon atoms, or any number within this range.
- alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, t-butyl, 2-butenyl, 2-butynyl, n-pentyl, 3-(2- methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyI and 2- methylpentyl.
- Alkoxy radicals are oxygen ethers formed from the previously described straight or branched chain alkyl groups.
- the alkyl and alkoxy group may be independently substituted with one to five, preferably one to three groups selected from halogen (F, Cl, Br, I), oxo, OH, amino, carboxyl, and alkoxy.
- the alkyl and alkoxy group may also be independently linked to one or more PEG radicals (polyethylene glycol).
- PEG radicals polyethylene glycol.
- acyl as used herein, whether used alone or as part of a substituent group, means an organic radical having a carbonyl group linked to hydrocarbyl group having 1 to 7 carbon atoms (branched or straight chain or cyclic) derived from an organic acid by removal of the hydroxyl group.
- C 4 acyl can include (CO)CH 2 CH 2 CH2CH 3 and (CO)(CH 2 (CH) (CH 3 ) 2 ; similarly, C 6 acyl includes both (CO)(C 6 H 3 ) and (CO)(C 6 H 5 ).
- Aryl is a carbocyclic aromatic radical including, but not limited to, phenyl, 1- or 2- naphthyl and the like.
- the carbocyclic aromatic radical may be substituted by independent replacement of 1 to 3 of the hydrogen atoms thereon with halogen, OH, CN, mercapto, nitro, amino, cyano, optionally substituted CrC 8 -alkyl, optionally substituted alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl-amino, di(C ⁇ -C 8 -alkyl)amino, formyl, carboxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkanoyloxy, phenyl, carbamoyl, carboxamide, di-lower alkylcarbamoyloxy, phenoxycarbonyloxy group, lower alkylenedioxy, benzoyloxy, alkyl-CO-O-, alky
- heteroaryl represents a stable five or six- membered monocyclic or bicyclic aromatic ring system which consists of carbon atoms and from one to three heteroatoms selected from N, O and S.
- the heteroaryl group may be attached at any heteroatom or carbon atom, which results in the creation of a stable structure.
- heteroaryl groups include, but are not limited to benzofuranyl, benzothiophenyl, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, thiophenyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzoxazolyl, benzopyrazolyl, indolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl or quinolinyl.
- Prefered heteroaryl groups include pyridinyl, thiophenyl, furanyl, and quinolinyl.
- the heteroaryl group may have one to three substituents which are independently selected from halogen, OH, CN, mercapto, nitro, amino, cyano, optionally substituted C-i-Cs-alkyl, optionally substituted alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl-amino, di(C ⁇ -Cs- alkyl)amino, formyl, carboxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkanoyloxy, phenyl, carbamoyl, carboxamide, di-lower alkylcarbamoyloxy, phenoxycarbonyloxy group, lower alkylenedioxy, benzoyloxy, alkyl-CO-O-, alkyl-O
- heterocycle refers to an optionally substituted, fully or partially saturated, aromatic or nonaromatic, cyclic group which is, for example, a 4- to 7-membered monocyclic, 7- to 11- membered (or 9- to 10-membered) bicyclic (or heterobicyclyl), or 10- to 15- membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom containing ring.
- Each ring of the heterocyclic group containing a heteroatom may have 1 , 2, or 3 heteroatoms selected from nitrogen atoms, oxygen atoms, and sulfur atoms, where the nitrogen and sulfur heteroatoms may also optionally be oxidized.
- the nitrogen atoms may optionally be quaternized.
- the heterocyclic group may be attached at any heteroatom or carbon atom.
- Exemplary monocyclic heterocyclic groups include pyrrolidinyl; oxetanyl; pyrazolinyl; imidazolinyl; imidazolidinyl; oxazolyl; oxazolidinyl; isoxazolinyl; thiazolidinyl; isothiazolidinyl; tetrahydrofuryl; piperidinyl; piperazinyl; 2- oxopiperazinyl; 2-oxopiperidinyl; 2-oxopyrrolidinyl; 4-piperidonyl; tetrahydropyranyl; tetrahydrothiopyranyl; tetrahydrothiopyranyl sulfone; morpholinyl; thiomorpholinyl; thiomorpholinyl sulfoxide; thiomorpholinyl sulfone; 1 ,3-dioxolane; dioxanyl; thietanyl
- bicyclic heterocyclic groups include quinuclidinyl; tetrahydroisoquinolinyl; dihydroisoindolyl; dihydroquinazolinyl (such as 3,4- dihydro-4-oxo-quinazolinyl); dihydrobenzofuryl; dihydrobenzothienyl; dihydrobenzothiopyranyl; dihydrobenzothiopyranyl sulfone; dihydrobenzopyranyl; indolinyl; isochromanyl; isoindolinyl; benzimidazolyl, benzthiazolyl; piperonyl; tetrahydroquinolinyl; and the like.
- the heterocyclyl may be independently substituted with one to five, preferably one to three groups selected from halogen, OH, CN, mercapto, nitro, amino, cyano, optionally substituted C ⁇ -C 8 - alkyl, optionally substituted alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkyl- amino, di(C ⁇ -C 8 -alkyl)amino, formyl, carboxyl, alkoxycarbonyl, alkoxycarbonyloxy, alkanoyloxy, phenyl, carbamoyl, carboxamide, di-lower alkylcarbamoyloxy, phenoxycarbonyloxy group, lower alkylenedioxy, benzoyloxy, alkyl-CO-O-, alkyl-O-CO-, -CONH 2 , alkyl-O-CO-0-, or alkyl-CO-
- biasing includes a heteroaryl linked to a phenyl, a phenyl linked to a heteroaryl (such as furan, pyridine, thiophene ), and a phenyl linked to a phenyl.
- heteroaryl such as furan, pyridine, thiophene
- phenyl-phenyl, heteroaryl-phenyl and phenyl-heteroaryl include:
- composition is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
- combined administration includes co-administration wherein: ) the two or more agents are administered to a subject at substantially similar times; and 2) the two or more agents are administered to a subject at different times, at independent intervals which may or may not overlap or coincide.
- subject refers to an animal, preferably a mammal, most preferably a human, who is the object of treatment, observation or experiment.
- RXR modulator refers to Retinoid-X receptor agonists, partial agonists, or antagonists. Preferably the modulator increases insulin sensitivity. According to one aspect, the modulator is an RXR agonist.
- Diabetes, Syndrome X, and associated symptoms or complications include such conditions as IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.
- Examples of a prediabetic state includes IGT and IFG.
- joint effective amount means that amount of each active compound or pharmaceutical agent, alone or in combination, that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
- the term "jointly effective amount” refers to that amount of each active compound or pharmaceutical agent, alone or in combination, that inhibits in a subject the onset or progression of a disorder as being sought by a researcher, veterinarian, medical doctor or other clinician, the delaying of which disorder is mediated by the modulation of glucose reabsorption activity or other antidiabetic agent activity or both.
- the present invention provides combinations of two or more drugs wherein, for example, (a) each drug is administered in an independently therapeutically or prophylactically effective amount; (b) at least one drug in the combination is administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but is therapeutic or prophylactic when administered in combination with the second or additional drugs according to the invention; or (c) both drugs are administered in an amount that is sub-therapeutic or sub-prophylactic if administered alone, but are therapeutic or prophylactic when administered together.
- protecting groups refer to those moieties known in the art that are used to mask functional groups; protecting groups may be removed during subsequent synthetic transformations or by metabolic or other in vivo administration conditions. During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known in the art. Examples of hydroxyl and diol protecting groups are provided below.
- Protection for the hydroxyl group includes methyl ethers, substituted methyl ethers, substituted ethyl ethers, substitute benzyl ethers, and silyl ethers.
- substituted Methyl Ethers include methyoxymethyl, methylthiomethyl, f-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl, benzyloxymethyl, p-methoxybenzyloxymethyl, (4-methoxyphenoxy)methyl, t- butoxymethyl, 4-pentenyloxymethyI, siloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-
- substituted ethyl ethers include 1-ethoxyethyl, 1-(2- chloroethoxy)ethyl, 1 -methyl- 1-methoxyethyl, 1-methyl-1-benzyloxyethyl, 1- methyl-1-benzyloxy-2-fluoroethyl, 2,2,2-trichloroethyl, 2-trimethylsilylethyl, 2- (phenylselenyl)ethyl, f-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4- dinitrophenyl, benzyl, and polyethyleneglycol ethers.
- substituted benzyl ethers include p-methoxybenzyl, 3,4- dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2- and 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p, p'-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, - naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p- methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4'- bromophenacyloxy)phenyldiphenylmethyl, 4,4',4"-tris(4,5- dichlorophthalimidophen
- silyl Ethers examples include trimethylsilyl, triethylsilyl, triisopropylsilyl, dimethylisopropylsilyl, diethylisopropylsilyl, dimethylthexylsilyl, t- butyldimethylsilyl, f-butyldiphenylsilyl, tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl, and f-butylmethoxyphenylsilyl.
- esters In addition to ethers, a hydroxyl group may be protected as an ester.
- esters include formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, p-P- phenylacetate, 3-phenylpropionate, 4-oxopentanoate(levulinate), 4,4- (ethylenedithio)pentanoate, pivaloate, adamantoate, crotonate, 4- methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6- trimethylbenzoate(mesitoate), and polyethyleneglycol esters.
- Carbonates examples include methyl, 9-fluorenylmethyl, ethyl, 2,2,2- trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, 2- (triphenylphosphonio)ethyl, isobutyl, vinyl, allyl, p-nitrophenyl, benzyl, p- methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, S-benzyl thiocarbonate, 4-ethoxy-1 -naphthyl, methyl dithiocarbonate, and polyethyleneglycol carbonates.
- assisted Cleavage examples include 2-iodobenzoate, 4-azidobutyrate,
- miscellaneous esters examples include 2,6-dichloro-4- methylphenoxyacetate, 2,6-dichloro-4-(1 ,1 ,3,3- tetramethylbutyl)phenoxyacetate, 2,4-bis(1 , 1 -dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2- butenoate(tigloate), o-(methoxycarbonyl)benzoate, p-P-benzoate, - naphthoate, nitrate, alkyl N,N,N',N'-tetramethylphosphorodiamidate, N- , phenylcarbamate, borate, dimethylphosphinothioyl, and 2,4- dinitrophenylsulfenate
- Sulfonates examples include sulfate, methanesulfonate(mesylate), benzylsulfonate, and tosylate.
- Cyclic Acetals and Ketals examples include methylene, ethylidene, 1-f- butylethylidene, 1-phenylethylidene, (4-methoxyphenyl)ethylidene, 2,2,2- trichloroethylidene, acetonide (isopropylidene), cyclopentylidene, cyclohexylidene, cycloheptylidene, benzylidene, p-methoxybenzylidene, 2,4- dimethoxybenzylidene, 3,4-dimethoxybenzylidene, and 2-nitrobenzylidene.
- Cyclic Ortho Esters examples include methoxymethylene, ethoxymethylene, dimethoxymethylene, 1-methoxyethylidene, 1-ethoxyethylidine, 1 ,2- dimethoxyethylidene, ⁇ -methoxybenzylidene, 1-(N,N-dimethylamino)ethylidene derivative, ⁇ -(N,N-dimethylamino)benzylidene derivative, and 2-oxacyclopentylidene.
- silyl derivatives examples include di- f-butylsilylene group, and 1 ,3- (1 ,1 ,3,3-tetraisopropyldisiloxanyIidene) derivative.
- SGLTs sodium-glucose cotransporters
- SGLT1 is present in intestinal and renal epithelial cells (Lee et al., 1994)
- SGLT2 is found in the epithelium of the kidney (You et al., 1995, MacKenzie et al., 1994).
- Glucose absorption in the intestine is primarily mediated by SGLT1 , a high-affinity low-capacity transporter with a Na + :glucose transport ratio of 2:1.
- SGLT2 also known as SAAT1 , transports Na + and glucose at a ratio of 1 :1 and functions as a low-affinity high-capacity transporter.
- SAAT1 transports Na + and glucose at a ratio of 1 :1 and functions as a low-affinity high-capacity transporter.
- Renal reabsorption of glucose is mediated by SGLT1 and SGLT2 (Silverman et al., 1992; Deetjen et al., 1995).
- Plasma glucose is filtered in the glomerulus and is transepithelially reabsorbed in the proximal tubules.
- SGLT1 and SGLT2 are located in the apical plasma membranes of the epithelium and derive their energy from the inward sodium gradient created by the Na + /K + ATPase pumps located on the basolateral membrane. Once reabsorbed, the elevated cytosolic glucose is then transported to the interstitial space by facilitated glucose transports (GLUT1 and GLUT2).
- a therapeutically or prophylactically effective amount of an SGLT inhibitor such as that sufficient to increase urine glucose excretion, or to decrease plasma glucose, in a subject by a desired amount per day, can be readily determined using methods established in the art. Recently, it has been found that phlorizin, a natural glycoside present in barks and stems of
- Rosaceae e.g., apple, pear, etc.
- phlorizin inhibits the renal tubular glucose reabsorption and promotes the excretion of glucose so that the glucose level in a plasma is controlled at a normal level for a long time via subcutaneous daily administration (Journal of Clinical Investigation, 1987, Vol. 79, p. 1510).
- SGLT inhibitors include alkyl- and phenyl-glucosides, 1-5- isoquinolinesulfonyl)-2-methylpiperazine-HCI (indirectly via protein kinase C), p- chloromercuribenzoate (PCMB), N,N'-dicyclohexylcarbodiimide (DCCD), copper and cadmium ions, and trivalent lanthanides.
- Ri is H, or C ⁇ - alkyl; or R ⁇ is absent where the dashed line between NR 1 and X is present,
- Y is CH, where X is C-Q-Z;
- Z is substituted or unsubstituted, and is selected from C 3 - 7 cycloalkyl, phenyl, a 5- or 6- membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, a 9- or 10-membered fused bicyclyl (such as naphthyl), and a fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms (and preferably between 1 and 3 or between 1 and 2 heteroatoms) independently selected from N, O, and S;
- P H, C 1 - 7 acyl, or (C1-6 alkoxy)carbonyl
- Examples of preferred compounds of Formula (IV) include: (a) Ri is H or absent; (b) Z is independently substituted with between 1 and 3 substituents independently selected from C 1 - 4 alkoxy, phenoxy, C 1 - 4 alkyl, C 3 - 6 cycloalkyl, halo, hydroxy, cyano, amino, C 1 - 4 alkylthio, C 1 .
- Preferred examples of compounds of the invention include: 3-(4-Ethylbenzyl)-5-( ⁇ -D-glucopyranosyl)-1 H-indole; 5-( ⁇ -D-Glucopyranosyl)-3-(4- methoxybenzyl)-1 H-indole; 5-( ⁇ -D-Glucopyranosyl)-3-[2-(4-methoxyphenyl)-ethyl]-1 H- indole; and 3-(4-Ethylbenzyl)-4-( ⁇ -D-glucopyranosyl)-1 H-indole.
- Additional preferred compounds include those selected from 2-(4- Ethylbenzyl)-4-( ⁇ -D-glucopyranosyl)-1 H-indole; 3-[2-(2,3-Dihydro-benzofuran- 5-yl)-ethyl]-5-( ⁇ -D-glucopyranosyl)-1 H-indole; 5-( ⁇ -D-Glucopyranosyl)-3-(5- ethyl-2-thienyl)-1 H-indole; 3-(4-Ethylbenzyl)-4-( ⁇ -D-glucopyranosyl)-3H- benzimidazole; 3-(4-Ethylbenzyl)-4-( ⁇ -D-glucopyranosyl)-1 ,3-dihydro- benzoimidazol-2-one and 3-(4-Ethylbenzyl)-4-( ⁇ -D-glucopyranosyl)-3H- benzotriazole.
- the most preferred compounds are selected from: 3-(4-Ethylbenzyl)-5-( ⁇ -D- glucopyranosyl)-1 H-indole; 2-(4-Ethylbenzyl)-4-( ⁇ -D-glucopyranosyl)-1 H-indole; 5-( ⁇ -D-Glucopyranosyl)-3-(5-methyl-2-thienyl)-1 H-indole; 3-(4-Ethylbenzyl)-4- ( ⁇ -D-glucopyranosyl)-3H-benzimidazole and 3-(4-Ethylbenzyl)-4-( ⁇ -D- glucopyranosyl)-3H-benzotriazole.
- One aspect of the invention features compounds of formula (IV). These compounds can be made according to traditional synthetic organic methods or combinatorial or matrix synthesis methods. The following schemes and chemical Examples 1-4 provide general guidance.
- the indole nitrogen of compounds of formula 2, where n is 1 or 2 can be deprotected by treatment with an aqueous base such as sodium hydroxide in refluxing ethanol to remove the N,N-diethylcarbamyl group followed by reprotection with terf-butlydimethylsilyl (TBDMS) group (P 2 ) by treatment with ter -butyldimethylsilyl chloride using known procedures to yield 5-bromo indole derivative 5.
- a compound of formula 5, where n is 1 can be prepared in three steps from commercial available sources of formula 3.
- the sodium salt of 7 can be treated with an alkyl halide to give the N-alkylated (Ri) product 9, which was undergone hydrogenolysis as previously described to provide compound of formula 10 where P is H.
- N-(2-Bromo-6-nitro-phenyl)-acetamide could be heated under acidic condition to remove the acetyl group then alkylated with substituted benzyl, aryl or heteroaryl alkyl halides, acylated with benzoyl or phenylacetyl chlorides followed by LAH or borane reduction or reductively aminated with substituted benzaldehydes in the presence of sodium cyanoborohydride to provide compounds of formula 9.
- the nitro group could then be reduced using reagents such as tin (II) chloride or iron in acetic acid to obtain compounds of formula 11 wherein the bromine is attached at position V in claim 1.
- the aniline nitrogen of commercially available 4-Bromo-2- nitroaniline could be acetylated or alternatively protected with an appropriate protecting group such as toluenesulfonyl or benzenesulfonyl to yield compounds of formula 10 wherein R' is the protecting group.
- the nitro group could then be reduced to a primary amine with tin (II) chloride and subsequently alkylated by treatment with substituted benzyl, aryl or heteroaryl alkyl halides, under basic conditions or reductively aminated with substituted benzaldehydes in the presence of sodium cyanoborohydride.
- the primary amine could be acylated with benzoyl or phenylacetyl chlorides followed by LAH or borane reduction.
- Final removal of the nitrogen protecting group using procedures known in the art could provide compounds of formula 11 wherein the bromine is attached at position W in claim 1.
- Methylation of compounds of formula 12 with iodomethane in the presence of a base can afford compounds of formula 16.
- Compounds of formula 13 can be treated with base such as sodium hydride and alkylated with alkyl halides to provide compounds of formula 17 wherein Ri is alkyl.
- the unsubstituted nitrogen of compound of formula 13 can also be protected with an alkoxy carbonyl group as described by Meanwell et. al. [J. Org. Chem. 1995, 60, 1565 - 1582] to provide compounds of formula 17 wherein Ri is either an ethoxy carbonyl moiety or a t-butoxycarbonyl group.
- Formation of the C-glycosides can be accomplished by treating compounds of formula 14, 16 or 17 (compound 15 is omitted) with butyllithium at -78 °C prior to the addition of 2,3,4,6-tetra-O-benzyl- ⁇ -D-glucolactone followed by reduction of the resulting hemiacetal in the presence of excess triethylsilane and boron trifluoride diethyl etherate in an appropriate solvent such as dichloromethane as described by Czernecki and Ville (J. Org. Chem. 1989, 54, 610 - 612).
- Compounds of formula 18, wherein Ri is H can be prepared by removing the protection groups under basic condition (for ethoxy carbonyl group) or under acidic condition (for tert-butoxycarbonyl group) followed by debenzylation of the hydroxyl groups using palladium catalysts under hydrogenation conditions.
- Compounds of formula 18, wherein R1 is an alkyl group, or formula 19 can be formed by debenzylation of the hydroxyl groups using palladium catalysts under hydrogenation conditions.
- Compounds of formula 20 wherein R 3 is H can be prepared by a Raney nickel mediated cleavage of the 2-methylthio group as described by Townsend, et. al. (J. Med. Chem.
- Formation of the C-glycosides can be accomplished by treating compounds of formula 23 with butyllithium at -78° C prior to the addition of 2,3,4,6-tetra-O- benzyl- ⁇ -D-glucolactone as described in Scheme 1.
- the resulting lactol can be treated with silanes, such as triethylsilane, in a solvent such as dichloromethane at -30 °C, followed by deprotection of the TBDMS group with an aqueous base, such as sodium hydroxide, in refluxing THF to yield compounds of formula 24.
- Hydrogenolysis of glucopyranose 24 over palladium hydroxide (Pearlman's catalyst) at one atmosphere can provide compounds of formula 25 where P is H.
- the sodium salt of 24 can be treated with an alkyl halide to give the N- alkylated (Ri) product 26, followed by hydrogenolysis as previously described to provide compound of formula 27 where P is H.
- Ri N- alkylated
- Antidiabetic agents that can be used according to the invention, as a second, third, or subsequent antidiabetic agent, in a composition, formulation, or combination method of treatment (dosing regimen) include, but are not limited to the classes and compounds exemplified in Table 2.
- the invention features a combination therapy comprising administering a, glucose reabsorption inhibitor, such as an SGLT inhibitor, and one or more antidiabetic agent(s) for the treatment of diabetes or Syndrome X, or associated symptoms or complications thereof.
- a, glucose reabsorption inhibitor such as an SGLT inhibitor
- antidiabetic agent(s) for the treatment of diabetes or Syndrome X, or associated symptoms or complications thereof.
- glucose reabsorption inhibitors have a mechanism of action distinct from that of other antidiabetic agents, such as RXR modulators
- the disclosed combination may have the advantage of reducing the amount of either drug necessary to achieve combined therapeutic or pharmaceutical efficacy, relative to the use of either drug alone, thereby reducing one or more adverse side-effects, which often include weight gain, edema, cardiac hypertrophy, hepatohypertrophy, hypoglycemia, or hepatotoxicity, or any combination thereof.
- the invention provides a method for treating diabetes or Syndrome X, or complications thereof in a subject, said method comprising administering to said subject a jointly effective amount of a glucose reabsorption inhibitor in combination with a jointly effective amount of an antidiabetic agent, such as an RXR modulator.
- the antidiabetic agent is an RXR agonist or RXR antagonist that increases insulin sensitivity in the subject.
- an insulin sensitizer can increase glucose tolerance in a subject in an oral glucose tolerance test.
- the diabetes or Syndrome X, or associated symptoms or complication thereof is selected from IDDM, NIDDM, IGT, and IFG.
- This invention also provides a pharmaceutical composition comprising one or more glucose reabsorption inhibitors ( alone or in combination with one or more antidiabetic agents), and a pharmaceutically acceptable carrier.
- the antidiabetic agent is an RXR agonist or RXR antagonist that increases insulin sensitivity in the subject.
- the glucose reabsorption inhibitor is a SGLT1 and/or SGLT2 inhibitor.
- the salt or salts of the compounds of Formula (IV) refer to non-toxic "pharmaceutically acceptable salt or salts.”
- Other salts may, however, be useful in the preparation of compounds according to this invention or of their pharmaceutically acceptable salts.
- Representative organic or inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benezenesulfonic, oxalic, pamoic, 2- naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid.
- Representative basic/cationic salts include, but are not limited to, benzathine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc.
- the compounds of Formula (IV) or a pharmaceutically acceptable salt thereof may include an intramolecular salt thereof, or a solvate or hydrate thereof.
- the utility of the disclosed compounds, compositions, and combinations to treat disorders in glucose and lipid metabolism can be determined according to the procedures well known in the art (see the references listed below), as well as all the procedures described in US PATENT NOs. 5424406, 5731292, 5767094, 5830873, 6048842, WO01/16122 and WO01/16123 which are incorporated herein by reference.
- the compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal and parenteral administration.
- formulations are for oral administration.
- the present invention also provides pharmaceutical compositions comprising one or more glucose reabsorption inhibitors and one or more RXR modulators in association with a pharmaceutically acceptable carrier.
- the daily dosage of the products may be varied over a wide range from 1 to 1000 mg per adult human per day.
- the compositions are preferably provided in the form of tablets containing, 0.01 , 0.05, 0.1 , 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 or 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- the compounds may be administered on a regimen of 1, to 2 times per day.
- the dosages may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed.
- compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
- a pharmaceutical carrier e.g.
- a solid preformulation composition containing a homogeneous mixture of one or more glucose reabsorption inhibitors and one or more antidiabetic agents, or a pharmaceutically acceptable salt thereof.
- preformulation compositions as homogeneous, it is meant that the active ingredient or ingredients are dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules.
- This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0J to about 500 mg of the active ingredient or ingredients of the present invention.
- the tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include, aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.
- the liquid forms in suitably flavored suspending or dispersing agents may also include the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like.
- acacia for parenteral administration
- sterile suspensions and solutions are desired.
- Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
- the combinations of one or more glucose reabsorption inhibitors of the present invention, alone or in combination with one or more additional antidiabetic agents may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
- one or more glucose reabsorption inhibitors and/or one or more antidiabetic agents according to the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen.
- the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Wherein the present invention is directed to the administration of a combination, the compounds may be co-administered simultaneously, sequentially, or in a single pharmaceutical composition. Where the compounds are administered separately, the number of dosages of each compound given per day, may not necessarily be the same, e.g. where one compound may have a greater duration of activity, and will therefore, be administered less frequently.
- Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the strength of the preparation, the mode of administration, and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, will result in the need to adjust dosages.
- compositions of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- Liposomes can be formed from a variety of lipids, including but not limited to amphipathic lipids such as phosphatidylcholines, sphingomyelins, phosphatidylethanolamines, phophatidylcholines, cardiolipins, phosphatidylserines, phosphatidylglycerols, phosphatidic acids, phosphatidylinositols, diacyl trimethylammonium propanes, diacyl dimethylammonium propanes, and stearylamine, neutral lipids such as triglycerides, and combinations thereof. They may either contain cholesterol or may be cholesterol-free.
- compositions of the invention may have one or more asymmetric carbon atoms in their structure. It is intended that the present invention include within its scope the stereochemically pure isomeric forms of the compounds as well as their racemates.
- Stereochemically pure isomeric forms may be obtained by the application of art known principles. Diastereoisomers may be separated by physical separation methods such as fractional crystallization and chromatographic techniques, and enantiomers may be separated from each other by the selective crystallization of the diastereomeric salts with optically active acids or bases or by chiral chromatography. Pure stereoisomers may also be prepared synthetically from appropriate stereochemically pure starting materials, or by using stereospecific reactions.
- Some compounds in the compositions of the present invention may have various individual isomers, such as trans and cis, and various alpha and beta attachments (below and above the plane of the drawing).
- these isomers may be separated by conventional techniques such as preparative chromatography.
- the compounds may be prepared as a single stereoisomer or in racemic form as a mixture of some possible stereoisomers.
- the non-racemic forms may be obtained by either synthesis or resolution.
- the compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation.
- the compounds may also be resolved by covalent linkage to a chiral auxiliary, followed by chromatographic separation and/or crystallographic separation, and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using chiral chromatography. Unless otherwise noted, the scope of the present invention is intended to cover all such isomers or stereoisomers per se, as well as mixtures of cis and trans isomers, mixtures of diastereomers and racemic mixtures of enantiomers (optical isomers) as well.
- the therapeutic effect of the glucose reabsorption inhibitor administered in combination with one or more antidiabetic agent(s) in treating diabetes, Syndrome X, or associated symptoms or complications can be shown by methods known in the art.
- the following examples of combination treatment with SGLT inhibitors and other antidiabetic agents such as RXR modulators are intended to illustrate the invention but not to limit it.
- One aspect of the invention features compounds of formula (IV) as described above in the Summary section, the description, and the appended claims. These disclosed compounds may be made according to traditional synthetic organic chemistry methods or according to matrix or combinatorial chemistry methods.
- the Schemes and Examples 1-9 below provide general guidance and detailed examples of how the disclosed compounds may be prepared.
- A. 5-Bromo-3-formyl-indole-1 -carboxylic acid diethylamide To a suspension of sodium hydride (0.93 g, 37 mmol) in anhydrous THF (75 mL) was added dropwise a solution of 5-bromo-1 H-indole-3-carbaldehyde (7.5 g, 34 mmol) in anhydrous THF (60 ml) at 0 °C. After stirring at 0 °C for 15 min, N,N-diethylcarbamyl chloride (5.0 g, 37 mmol) was added dropwise into the reaction mixture. The mixture was warmed to room temperature and stirred overnight.
- the organic extracts were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo.
- the crude product was purified by chromatography on silica gel eluting with ethyl acetate / hexane (1 :4) to provide a mixture of the desired lactol and unreacted 2,3,4,6-tetra-O-benzyl- ⁇ -D- glucolactone (2.8 g, -50% of the desired lactol) as a light brown oil. This mixture was used directly to the next step without further purification.
- the title compound was prepared as a white solid, from 5-bromo-3-formyl- indole-1 -carboxylic acid diethylamide (Example 1 , Part A) and 4- methoxyphenyl-magnesium bromide by the same procedure as described in Example 1 , Part B to G).
- A. 5-Bromo-3-[2-(4-methoxy-phenyl)-ethyl]-indole-1 -carboxylic acid diethylamide To a solution of 4-methoxybenzyl triphenyphosphonium chloride (7.5 g, 18 mmol) in anhydrous THF (75 mL) at -78° C was added LDA (9.0 mL, 18 mmol) and the resulting reaction mixture was allowed to stir at -78° C for 1 h.
- the crude product was purified by chromatography on silica gel eluting with ethyl acetate / hexane (1 :4) to provide the mixture of alkenes (2.3 g, 90%, E:Z ⁇ 1 :1 ) as a brown oil.
- a solution of the above alkenes (2.3 g, 5.4 mmol) in dichloromethane (100 mL) was hydrogenated over Adam's catalyst (300 mg) under H 2 (15 psi) for 2 h. The catalyst was removed by filtration and the filtrate was concentrated in vacuo.
- the crude product was purified by chromatography on silica gel eluting with ethyl acetate / hexane (1 :4) to provide the title compound (1.43 g, 62%) as a colorless oil.
- A. (4-Bromo-1 H-indol-3-yl)-(4-ethyl-phenyl)-methanone To a suspension of AICI 3 (3.0 g, 22.5 mmol) in dichloromethane (50 mL) was added a solution of 4-bromoindole (2.21 g, 11.3 mmol) in dichloromethane (25 mL) at room temperature over the period of 20 mins, followed by the addition of a solution of 4-ethyl-benzoyl chloride (2.5 mL, 17 mmol) in dichloromethane (25 mL) over the period of 20 mins.
- CHO-K1 cells stably expressing human SGLT1 or human SGLT2 Transfection of CHO-K1 cells was performed using DMRIE-C reagent (Life Technologies, Gaithersburg, MD). Transfectants were then selected in the presence of the antibiotic G418 (Gibco-BRL, Grand Island, NY) at 400 ⁇ g/ml. Individual clones were then characterized using the functional assay described below.
- Cell-based assay for sodium-dependent glucose transport Cell lines stably expressing human SGLT1 or SGLT2 were then used for functional analysis of Na+-dependent glucose uptake. Briefly, cells were plated at a density of 65,000 cells per well in a 96-well plate and allowed to grow for 48 hours. Cells were subsequently washed one time with Assay Buffer (50 mM HEPES pH 7.4, 20 mM Tris, 5 mM KCI, 1 mM MgCI 2 , 1 mM CaCI 2 and 137 mM NaCI) and treated with compound in the absence or presence of NaCI for 15 minutes. Cells were then labeled with 14 C - ⁇ -methylglucopyranoside (AMG, Sigma, St.
- Assay Buffer 50 mM HEPES pH 7.4, 20 mM Tris, 5 mM KCI, 1 mM MgCI 2 , 1 mM CaCI 2 and 137 mM NaCI
- mice Male Zucker Diabetic Fatty (ZDF) rats (7-8 weeks) were obtained from Charles River. Animals were maintained on a 12-hour light/dark cycle in a temperature- controlled room. Animals were given ad libitum access to food (standard rodent diet Purina 5008) and water. Animals were fasted for 12 hours prior to initiation of the experiment. On the morning of the experiment, animals were administered vehicle (0.5 % methylcellulose) or compound by oral gavage (1 ml/kg). After one hour, animals received an oral glucose challenge (4 ml/kg of 50% solution) and were immediately placed in metabolism cages. Animals were given free access to water and urine was collected for 4 hours. Urinary glucose was quantified using the Trinder Reagent (Sigma). EXAMPLE 3
- mice Female db/db mice (6-7 weeks of age/Jackson Labs, ME) are treated daily for 11 days with vehicle (0.5% methylcellulose), an RXR agonist (0.1 -10 mpk (mg/kg)), an SGLT inhibitor (100 mpk), or an RXR agonist plus SGLT inhibitor.
- Mice are then bled by retro-orbital sinus puncture into 2 mL heparinized polypropylene tubes on ice. Plasma samples are then assayed for glucose, insulin, triglycerides, and free fatty acids. Livers are excised, weighed and frozen.
- the SGLT inhibitors and RXR agonists have distinct mechanisms of action. Improved glycemic control, measured as a decrease in plasma glucose, plasma insulin, plasma free fatty acids, or plasma triglycerides, or a combination thereof, can be observed at lower concentrations of an RXR agonist when given in combination with an SGLT inhibitor. Therefore, a leftward shift in the dose-response curve for effect of an RXR agonist on the above parameters can become apparent. In addition, the weight gain observed following treatment with RXR agonists is less pronounced when given with the SGLT inhibitor, since SGLT inhibitors' promotion of the urinary excretion of glucose and loss of calories from the body is demonstrated by reduction in weight or weight gain.
- SGLT inhibitors promote a mild diuresis
- the edema (and the edematous weight gain) commonly observed after treatment with RXR agonists can be less pronounced or absent.
- the decreased side effects can include such conditions as fatty liver, increased liver weight, body weight gain, heart weight gain, edema, cardiac hypertrophy, hepatohypertrophy, hypoglycemia, and hepatotoxicity, or any combination thereof.
- mice (6 weeks of age/GMI) are treated daily for 28 days with vehicle (0.5% methylcellulose), an RXR agonist (0.1 mpk-10mpk), SGLT inhibitor (3-100 mpk), or an RXR agonist plus SGLT inhibitor.
- Rats are weighed and anesthetized with CO 2 /O 2 (70:30). Rats are then bled by retro- orbital sinus puncture into 2 mL heparinized polypropylene tubes on ice. Rats then receive a glucose challenge (2 g/kg p.o) and are placed in metabolism cages for the urine collection (4 hours). Animals are then sacrificed and epididymal fat pads, livers, and hearts are excised, weighed and frozen for histological examination. Plasma samples are then assayed for glucose, HbAlc, insulin, hematocrit, plasma drug levels, total cholesterol, HDL, free fatty acids, and triglycerides. Urine volume and urinary glucose, protein, osmolarity, electrolytes (Na, K, Cl), BUN and creatinine are measured.
- the SGLT inhibitors and RXR agonists have distinct mechanisms of action. Improved glycemic control, measured as a decrease in plasma glucose, HbAlc, plasma insulin, or plasma triglycerides, or a combination thereof, can be observed at lower concentrations of RXR agonists when given in combination with an SGLT inhibitor. Therefore, a leftward shift in the dose- response curve for effect of RXR agonists on the above parameters can become apparent. In addition, the weight gain observed following treatment with RXR agonists is less pronounced when given with the SGLT inhibitor, since SGLT inhibitors' promotion of the urinary excretion of glucose and loss of calories from the body is demonstrated by reduction in weight or weight gain.
- the edema (and the edematous weight gain) commonly observed after treatment with RXR agonists can be less pronounced or absent. This can be demonstrated by a reduction in the RXR agonist-induced increase in heart weight. A reduction in the amount of RXR agonists necessary to achieve efficacy in turn improves the side-effect profile.
- the decreased side effects can include such conditions as fatty liver, increased liver weight, body weight gain, heart weight gain, edema, cardiac hypertrophy, hepatohypertrophy, hypoglycemia, and hepatotoxicity, or any combination thereof.
- an SGLT inhibitor in combination with an antidiabetic agents such as an RXR modulator mprove the status of other markers of diabetes mellitus including glycosylated hemoglobin (Hgb A1 C) levels.
- an antidiabetic agents such as an RXR modulator
- the oral administration of an SGLT inhibitor in combination with one or more RXR modulators can reduce body weight or body weight gain as well as liver weight or liver weight gain, compared to administration of one or more RXR modulators alone.
- a compound of Formula (IV) in combination with one or more antidiabetic agents such as an RXR agonist that increases insulin sensitivity
- one or more antidiabetic agents such as an RXR agonist that increases insulin sensitivity
- the jointly effective dosage for antidiabetic agents disclosed herein may be readily determined by those skilled in the art based on standard dosage guidelines.
- such combined administration can be effective to accomplish reduction of body weight, body weight gain, liver weight, or liver weight gain in the subject.
- a method comprising (a) administering to a subject a jointly effective amount of a glucose reabsorption inhibitor; and (b) administering to the subject a jointly effective amount of an antidiabetic agent such as an RXR modulator can be used to reduce body weight, body weight gain, or liver weight of the subject in need thereof, wherein the combined administration can be in any order and the combined jointly effective amounts provide the desired therapeutic effect.
- a method comprising (a) administering to a subject a jointly effective amount of a glucose reabsorption inhibitor; and (b) administering to the subject a jointly effective amount of an antidiabetic agent can be used to control body weight, body weight gain, liver weight, or liver weight gain of the subject having diabetes, Syndrome X, or associated symptoms or complications, wherein the combined administration can be in any order and the combined jointly effective amounts providing the desired therapeutic effect.
- Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient's sex, age, weight, diet, time of administration and concomitant diseases, will result in the need to adjust dosages.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004261660A AU2004261660A1 (en) | 2003-08-01 | 2004-07-30 | Substituted fused heterocyclic C-glycosides |
YUP-2006/0321A RS20060321A (en) | 2003-11-12 | 2004-07-30 | Substituted fused heterocyclic c-glycosides |
EP04779628A EP1679965A4 (en) | 2003-08-01 | 2004-07-30 | Substituted fused heterocyclic c-glycosides |
CA002549015A CA2549015A1 (en) | 2003-08-01 | 2004-07-30 | Substituted fused heterocyclic c-glycosides |
EA200601552A EA009768B1 (en) | 2003-08-01 | 2004-07-30 | Substituted fused heterocyclic c-glycosides |
IL175489A IL175489A0 (en) | 2003-08-01 | 2006-05-08 | Substituted fused heterocyclic c-glycosides |
IS8445A IS8445A (en) | 2003-11-12 | 2006-05-09 | Substitute molten heterocyclic c-glycoside |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49152303P | 2003-08-01 | 2003-08-01 | |
US49153403P | 2003-08-01 | 2003-08-01 | |
US60/491,534 | 2003-08-01 | ||
US60/491,523 | 2003-08-01 | ||
US51921003P | 2003-11-12 | 2003-11-12 | |
US60/519,210 | 2003-11-12 | ||
US57973004P | 2004-06-15 | 2004-06-15 | |
US60/579,730 | 2004-06-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005012318A2 true WO2005012318A2 (en) | 2005-02-10 |
WO2005012318A3 WO2005012318A3 (en) | 2005-12-15 |
Family
ID=34120044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/024625 WO2005012318A2 (en) | 2003-08-01 | 2004-07-30 | Substituted fused heterocyclic c-glycosides |
Country Status (9)
Country | Link |
---|---|
US (4) | US7094763B2 (en) |
EP (1) | EP1679965A4 (en) |
AR (1) | AR048376A1 (en) |
AU (1) | AU2004261660A1 (en) |
CA (1) | CA2549015A1 (en) |
EA (1) | EA009768B1 (en) |
IL (1) | IL175489A0 (en) |
TW (1) | TW200521131A (en) |
WO (1) | WO2005012318A2 (en) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005085237A1 (en) * | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
WO2007128761A2 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Uses of dpp-iv inhibitors |
WO2008013280A1 (en) | 2006-07-27 | 2008-01-31 | Chugai Seiyaku Kabushiki Kaisha | Substituted spiroketal derivative and use thereof as drug for treating diabetes |
WO2008013277A1 (en) | 2006-07-27 | 2008-01-31 | Chugai Seiyaku Kabushiki Kaisha | Fused ring spiroketal derivative and use thereof as drug for treating diabetes |
WO2008044762A1 (en) | 2006-10-13 | 2008-04-17 | Chugai Seiyaku Kabushiki Kaisha | Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes |
FR2926021A1 (en) * | 2008-01-03 | 2009-07-10 | Oreal | Cosmetic use of a C-glycoside derivative e.g. as an agent acting on the microcirculation and for the preparation of a composition to stimulate dermal blood circulation and/or for preventing insufficiency of superficial venous system |
US7579449B2 (en) | 2004-03-16 | 2009-08-25 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2009124638A1 (en) | 2008-04-07 | 2009-10-15 | Merck Patent Gmbh | Glucopyranoside derivatives |
US7662790B2 (en) | 2005-04-15 | 2010-02-16 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7683160B2 (en) | 2005-08-30 | 2010-03-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7687469B2 (en) | 2004-12-16 | 2010-03-30 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7713938B2 (en) | 2005-05-03 | 2010-05-11 | Boehringer Ingelheim International Gmbh | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7745414B2 (en) | 2006-02-15 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US7767651B2 (en) | 2005-01-28 | 2010-08-03 | Chugai Seiyaku Kabushiki Kaisha | Spiroketal derivatives and use thereof as diabetic medicine |
US7772378B2 (en) | 2005-02-23 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US7776830B2 (en) | 2006-05-03 | 2010-08-17 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US7781577B2 (en) | 2006-09-29 | 2010-08-24 | Lexicon Pharmaceuticals, Inc. | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
WO2010128152A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
US7847074B2 (en) | 2005-09-15 | 2010-12-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof |
US7846945B2 (en) | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
US7851602B2 (en) | 2005-07-27 | 2010-12-14 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
AU2010276369B2 (en) * | 2009-07-22 | 2013-07-04 | Med-El Elektromedizinische Geraete Gmbh | Magnetic attachment arrangement for implantable device |
US8507450B2 (en) | 2005-09-08 | 2013-08-13 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
US8551957B2 (en) | 2007-08-16 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
US8802842B2 (en) | 2009-09-30 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form |
US9024010B2 (en) | 2009-09-30 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
CN110041378A (en) * | 2019-05-25 | 2019-07-23 | 扬州工业职业技术学院 | A kind of benzoxazoles ketoside and its preparation process and application |
US10400214B2 (en) | 2008-12-23 | 2019-09-03 | Boco Silicon Valley, Inc. | Target populations of oligodendrocyte precursor cells and methods of making and using same |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
US10752604B2 (en) | 2016-01-04 | 2020-08-25 | Je II Pharmaceutical Co., Ltd. | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1980560T3 (en) * | 2003-03-14 | 2011-11-30 | Astellas Pharma Inc | C-glycoside derivatives for the treatment of diabetes |
US8785403B2 (en) | 2003-08-01 | 2014-07-22 | Mitsubishi Tanabe Pharma Corporation | Glucopyranoside compound |
PL1651658T5 (en) | 2003-08-01 | 2020-11-30 | Mitsubishi Tanabe Pharma Corporation | Novel compounds having inhibitory activity against sodium-dependant transporter |
EP1679965A4 (en) * | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | Substituted fused heterocyclic c-glycosides |
WO2006010557A1 (en) * | 2004-07-27 | 2006-02-02 | Boehringer Ingelheim International Gmbh | D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof |
WO2006035796A1 (en) * | 2004-09-29 | 2006-04-06 | Kissei Pharmaceutical Co., Ltd. | 1-(β-D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF |
EP1813611B1 (en) * | 2004-11-18 | 2014-10-01 | Kissei Pharmaceutical Co., Ltd. | 1-substituted-3- beta-d-glycopyranosylated nitrogenous hetero- cyclic compounds and medicines containing the same |
AR053329A1 (en) * | 2005-01-31 | 2007-05-02 | Tanabe Seiyaku Co | INDOL DERIVATIVES USEFUL AS INHIBITORS OF GLUCOSE CONVEYORS DEPENDENT ON SODIUM (SGLT) |
TWI365186B (en) | 2005-01-31 | 2012-06-01 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
CA2599550A1 (en) * | 2005-03-11 | 2006-09-21 | Elixir Pharmaceuticals, Inc. | Sirt inhibitors that bind to nad |
KR101380813B1 (en) * | 2005-04-20 | 2014-04-04 | 깃세이 야쿠힌 고교 가부시키가이샤 | Combined pharmaceutical preparation for treatment of type 2 diabetes |
TW200726755A (en) * | 2005-07-07 | 2007-07-16 | Astellas Pharma Inc | A crystalline choline salt of an azulene derivative |
JP5230613B2 (en) | 2006-05-23 | 2013-07-10 | テラコス・インコーポレイテッド | Glucose transporter inhibitor and method of use thereof |
TWI418556B (en) * | 2006-07-27 | 2013-12-11 | Mitsubishi Tanabe Pharma Corp | Indole derivatives |
CA2671699C (en) * | 2006-12-04 | 2014-07-08 | Janssen Pharmaceutica N.V. | Thienyl-containing glycopyranosyl derivatives as antidiabetics |
UY30730A1 (en) * | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | CRYSTAL FORM OF HEMIHYDRATE 1- (B (BETA) -D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE |
CN101568537A (en) * | 2006-12-21 | 2009-10-28 | 安斯泰来制药有限公司 | Method for producing C-glycoside derivative and synthetic intermediate thereof |
US7795228B2 (en) * | 2006-12-28 | 2010-09-14 | Theracos, Inc. | Spiroheterocyclic glycosides and methods of use |
KR101506935B1 (en) | 2007-04-02 | 2015-03-31 | 테라코스, 인코포레이티드 | Benzylic glycoside derivatives and methods of use |
SG188800A1 (en) | 2007-08-23 | 2013-04-30 | Theracos Inc | Benzylbenzene derivatives and methods of use |
KR101552187B1 (en) | 2007-09-10 | 2015-09-10 | 얀센 파마슈티카 엔.브이. | Process for the preparation of compounds useful as inhibitors of sglt |
UA101004C2 (en) | 2007-12-13 | 2013-02-25 | Теракос, Инк. | Derivatives of benzylphenylcyclohexane and use thereof |
CL2008003653A1 (en) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition. |
CN102177147A (en) | 2008-08-22 | 2011-09-07 | 泰拉科斯有限公司 | Processes for the preparation of SGLT2 inhibitors |
US9056850B2 (en) * | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
US20110009347A1 (en) * | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
CA2767258C (en) | 2009-07-10 | 2016-09-13 | Janssen Pharmaceutica Nv | Crystallisation process for 1-(.beta.-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene |
CN101991580B (en) * | 2009-08-28 | 2013-03-20 | 杏辉天力(杭州)药业有限公司 | Application of lanostane and poria cocos extracts in diabetes treatment |
EA024368B1 (en) * | 2009-10-14 | 2016-09-30 | Янссен Фармацевтика Нв | Process for the preparation of compounds useful as inhibitors of sglt2 |
AP3099A (en) | 2009-11-02 | 2015-01-31 | Pfizer | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol de derivatives |
JP6227406B2 (en) | 2010-05-11 | 2017-11-08 | ヤンセン ファーマシューティカ エヌ.ベー. | Pharmaceutical formulations containing 1- (β-D-glucopyranosyl) -2-thienyl-methylbenzene derivatives as inhibitors of SGLT |
WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
CA2832938C (en) | 2011-04-13 | 2019-09-03 | Janssen Pharmaceutica Nv | Process for the preparation of compounds useful as inhibitors of sglt2 |
US9035044B2 (en) | 2011-05-09 | 2015-05-19 | Janssen Pharmaceutica Nv | L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
WO2015051484A1 (en) | 2013-10-12 | 2015-04-16 | Theracos, Inc. | Preparation of hydroxy-benzylbenzene derivatives |
TN2017000426A1 (en) | 2015-04-07 | 2019-04-12 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions for combination therapy |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
WO2017141202A1 (en) | 2016-02-17 | 2017-08-24 | Lupin Limited | Complex of sglt2 inhibitor and process for preparation thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4584369A (en) * | 1981-07-31 | 1986-04-22 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl C-nucleosides |
US5334225A (en) | 1992-07-15 | 1994-08-02 | Kao Corporation | Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler |
US5731292A (en) * | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
CA2102591C (en) * | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
US6297363B1 (en) * | 1993-02-12 | 2001-10-02 | Nomura Co., Ltd. | Glycoside indoles |
US5830873A (en) | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5780483A (en) * | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
JP3059088B2 (en) * | 1995-11-07 | 2000-07-04 | 田辺製薬株式会社 | Propiophenone derivatives and their production |
AU719726B2 (en) * | 1996-12-26 | 2000-05-18 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivatives and process for preparing the same |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
JP2003531104A (en) | 1999-08-31 | 2003-10-21 | マキシア・ファーマシューティカルズ・インコーポレイテッド | Benzylidene-thiazolidinediones and analogs and their use in treating inflammation |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
US6627611B2 (en) * | 2000-02-02 | 2003-09-30 | Kotobuki Pharmaceutical Co Ltd | C-glycosides and preparation of thereof as antidiabetic agents |
WO2001064669A1 (en) | 2000-03-03 | 2001-09-07 | Pfizer Products Inc. | Pyrazole ether derivatives as anti-inflammatory/analgesic agents |
SK287183B6 (en) | 2000-03-17 | 2010-02-08 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives and the use of them |
US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
US6936590B2 (en) | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
ES2258141T3 (en) | 2001-04-11 | 2006-08-16 | Bristol-Myers Squibb Company | C-ARILO GLUCOSIDE AMINO ACIDS COMPLEX FOR DIABETES TREATMENT AND PROCEDURE. |
CA2448741C (en) | 2001-05-30 | 2010-06-22 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
CN100376592C (en) | 2001-06-20 | 2008-03-26 | 橘生药品工业株式会社 | Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
WO2003011880A1 (en) | 2001-07-31 | 2003-02-13 | Kissei Pharmaceutical Co., Ltd. | Glucopyrano syloxybenzyl benzene derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
US20030087843A1 (en) | 2001-09-05 | 2003-05-08 | Washburn William N. | O-pyrazole glucoside SGLT2 inhibitors and method of use |
US6617313B1 (en) | 2002-03-13 | 2003-09-09 | Council Of Scientific And Industrial Research | Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof |
US6562791B1 (en) * | 2002-03-29 | 2003-05-13 | Council Of Scientific And Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
AU2002246317A1 (en) | 2002-04-08 | 2003-10-27 | Council Of Scientific And Industrial Research | Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
PL1980560T3 (en) | 2003-03-14 | 2011-11-30 | Astellas Pharma Inc | C-glycoside derivatives for the treatment of diabetes |
JP2004300102A (en) | 2003-03-31 | 2004-10-28 | Kissei Pharmaceut Co Ltd | Condensed heterocyclic derivative, pharmaceutical composition containing the same and its pharmaceutical application |
EP1679965A4 (en) * | 2003-08-01 | 2009-05-27 | Janssen Pharmaceutica Nv | Substituted fused heterocyclic c-glycosides |
-
2004
- 2004-07-30 EP EP04779628A patent/EP1679965A4/en not_active Withdrawn
- 2004-07-30 US US10/903,136 patent/US7094763B2/en not_active Expired - Lifetime
- 2004-07-30 EA EA200601552A patent/EA009768B1/en not_active IP Right Cessation
- 2004-07-30 AU AU2004261660A patent/AU2004261660A1/en not_active Abandoned
- 2004-07-30 AR ARP040102728A patent/AR048376A1/en not_active Application Discontinuation
- 2004-07-30 TW TW093122974A patent/TW200521131A/en unknown
- 2004-07-30 WO PCT/US2004/024625 patent/WO2005012318A2/en active Application Filing
- 2004-07-30 CA CA002549015A patent/CA2549015A1/en not_active Abandoned
-
2006
- 2006-05-08 IL IL175489A patent/IL175489A0/en unknown
- 2006-06-15 US US11/453,728 patent/US7482330B2/en active Active
-
2008
- 2008-12-18 US US12/337,918 patent/US20090105162A1/en not_active Abandoned
-
2009
- 2009-09-11 US US12/557,728 patent/US7816328B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of EP1679965A4 * |
Cited By (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005085237A1 (en) * | 2004-03-04 | 2008-01-17 | キッセイ薬品工業株式会社 | Fused heterocyclic derivative, pharmaceutical composition containing the same, and pharmaceutical use thereof |
WO2005085237A1 (en) * | 2004-03-04 | 2005-09-15 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
US8058245B2 (en) | 2004-03-04 | 2011-11-15 | Kissei Pharmaceutical Co., Ltd. | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
CN1934103B (en) * | 2004-03-04 | 2011-06-01 | 橘生药品工业株式会社 | Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof |
US7579449B2 (en) | 2004-03-16 | 2009-08-25 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7687469B2 (en) | 2004-12-16 | 2010-03-30 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7767651B2 (en) | 2005-01-28 | 2010-08-03 | Chugai Seiyaku Kabushiki Kaisha | Spiroketal derivatives and use thereof as diabetic medicine |
US7772378B2 (en) | 2005-02-23 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7662790B2 (en) | 2005-04-15 | 2010-02-16 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7713938B2 (en) | 2005-05-03 | 2010-05-11 | Boehringer Ingelheim International Gmbh | Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US9127034B2 (en) | 2005-05-10 | 2015-09-08 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivates and intermediates therein |
US10442795B2 (en) | 2005-05-10 | 2019-10-15 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
US7851602B2 (en) | 2005-07-27 | 2010-12-14 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US7683160B2 (en) | 2005-08-30 | 2010-03-23 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
US8507450B2 (en) | 2005-09-08 | 2013-08-13 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments |
US7847074B2 (en) | 2005-09-15 | 2010-12-07 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof |
US7745414B2 (en) | 2006-02-15 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US7776830B2 (en) | 2006-05-03 | 2010-08-17 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
US8557782B2 (en) | 2006-05-03 | 2013-10-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
EP2351568A2 (en) | 2006-05-04 | 2011-08-03 | Boehringer Ingelheim International GmbH | Uses of dpp-iv inhibitors |
WO2007128761A2 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Uses of dpp-iv inhibitors |
WO2008013280A1 (en) | 2006-07-27 | 2008-01-31 | Chugai Seiyaku Kabushiki Kaisha | Substituted spiroketal derivative and use thereof as drug for treating diabetes |
WO2008013277A1 (en) | 2006-07-27 | 2008-01-31 | Chugai Seiyaku Kabushiki Kaisha | Fused ring spiroketal derivative and use thereof as drug for treating diabetes |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
US8476413B2 (en) | 2006-09-29 | 2013-07-02 | Lexicon Pharmaceuticals, Inc. | Sulfanyl-tetrahydropyran-based compounds and methods of their use |
EP2308841A2 (en) | 2006-09-29 | 2011-04-13 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as SGLT2 inhibitors |
US9365602B2 (en) | 2006-09-29 | 2016-06-14 | Lexicon Pharmaceuticals, Inc. | Sodium glucose co-transporter inhibitors and methods of their use |
US7781577B2 (en) | 2006-09-29 | 2010-08-24 | Lexicon Pharmaceuticals, Inc. | Inhibitors of sodium glucose co-transporter 2 and methods of their use |
WO2008044762A1 (en) | 2006-10-13 | 2008-04-17 | Chugai Seiyaku Kabushiki Kaisha | Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7846945B2 (en) | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
US8551957B2 (en) | 2007-08-16 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
FR2926021A1 (en) * | 2008-01-03 | 2009-07-10 | Oreal | Cosmetic use of a C-glycoside derivative e.g. as an agent acting on the microcirculation and for the preparation of a composition to stimulate dermal blood circulation and/or for preventing insufficiency of superficial venous system |
WO2009124638A1 (en) | 2008-04-07 | 2009-10-15 | Merck Patent Gmbh | Glucopyranoside derivatives |
AU2009235786B2 (en) * | 2008-04-07 | 2013-09-26 | Merck Patent Gmbh | Glucopyranoside derivatives |
US8399509B2 (en) | 2008-04-07 | 2013-03-19 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Glucopyranoside derivatives |
US10400214B2 (en) | 2008-12-23 | 2019-09-03 | Boco Silicon Valley, Inc. | Target populations of oligodendrocyte precursor cells and methods of making and using same |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
WO2010128152A1 (en) * | 2009-05-07 | 2010-11-11 | Novartis Ag | Fused heterocyclic c-glycosides for the treatment of diabetes |
AU2010276369B2 (en) * | 2009-07-22 | 2013-07-04 | Med-El Elektromedizinische Geraete Gmbh | Magnetic attachment arrangement for implantable device |
US8802842B2 (en) | 2009-09-30 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form |
US9024010B2 (en) | 2009-09-30 | 2015-05-05 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US9873714B2 (en) | 2009-09-30 | 2018-01-23 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
US11564886B2 (en) | 2011-03-07 | 2023-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US10596120B2 (en) | 2011-03-07 | 2020-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11090323B2 (en) | 2013-04-05 | 2021-08-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10258637B2 (en) | 2013-04-05 | 2019-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11833166B2 (en) | 2013-04-05 | 2023-12-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11918596B2 (en) | 2013-04-05 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US10752604B2 (en) | 2016-01-04 | 2020-08-25 | Je II Pharmaceutical Co., Ltd. | C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same |
CN110041378A (en) * | 2019-05-25 | 2019-07-23 | 扬州工业职业技术学院 | A kind of benzoxazoles ketoside and its preparation process and application |
Also Published As
Publication number | Publication date |
---|---|
US7094763B2 (en) | 2006-08-22 |
WO2005012318A3 (en) | 2005-12-15 |
AU2004261660A1 (en) | 2005-02-10 |
US7816328B2 (en) | 2010-10-19 |
CA2549015A1 (en) | 2005-02-10 |
EA009768B1 (en) | 2008-04-28 |
US20090105162A1 (en) | 2009-04-23 |
EP1679965A4 (en) | 2009-05-27 |
EP1679965A2 (en) | 2006-07-19 |
EA200601552A1 (en) | 2007-02-27 |
TW200521131A (en) | 2005-07-01 |
US7482330B2 (en) | 2009-01-27 |
AR048376A1 (en) | 2006-04-26 |
US20050037980A1 (en) | 2005-02-17 |
US20060229260A1 (en) | 2006-10-12 |
IL175489A0 (en) | 2009-02-11 |
US20100004160A1 (en) | 2010-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7482330B2 (en) | Substituted fused heterocyclic C-glycosides | |
US7820630B2 (en) | Substituted indole-O-glucosides | |
US7084124B2 (en) | Substituted indazole-O-glucosides | |
US7511020B2 (en) | Substituted benzimidazole-, benztriazole-, and benzimidazolone-O-glucosides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1120040014689 Country of ref document: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 175489 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 547051 Country of ref document: NZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004779628 Country of ref document: EP Ref document number: P-2006/0321 Country of ref document: YU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200603881 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2549015 Country of ref document: CA Ref document number: 1595/KOLNP/2006 Country of ref document: IN Ref document number: 1594/KOLNP/2006 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004779628 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004261660 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200601552 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2004261660 Country of ref document: AU Date of ref document: 20040730 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004261660 Country of ref document: AU |
|
ENPW | Started to enter national phase and was withdrawn or failed for other reasons |
Ref document number: PI0418617 Country of ref document: BR Kind code of ref document: A2 Free format text: INTERESSADO: O DEPOSITANTE. DESPACHO: PEDIDO CONSIDERADO RETIRADO EM RELACAO AO BRASIL POR TER SIDO INTEMPESTIVO, NOS TERMOS DO ART. 3O DA RESOLUCAO NO 254/2010, E COMBINADO COM A REGRA 49.6 DO PCT. |